Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Equity Ratio (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Equity Ratio for 7 consecutive years, with 0.78 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 0.56% to 0.78 in Q4 2025 year-over-year; TTM through Nov 2025 was 0.78, a 0.56% decrease, with the full-year FY2025 number at 0.78, down 0.56% from a year prior.
  • Equity Ratio was 0.78 for Q4 2025 at Nurix Therapeutics, up from 0.71 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.79 in Q4 2024 to a low of 0.54 in Q1 2024.
  • A 5-year average of 0.72 and a median of 0.74 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: dropped 27.11% in 2024, then soared 44.88% in 2025.
  • Nurix Therapeutics' Equity Ratio stood at 0.72 in 2021, then grew by 1.5% to 0.73 in 2022, then dropped by 22.63% to 0.56 in 2023, then skyrocketed by 39.64% to 0.79 in 2024, then decreased by 0.56% to 0.78 in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Equity Ratio are 0.78 (Q4 2025), 0.71 (Q3 2025), and 0.76 (Q2 2025).